Cross-reactive skin eruption with both carbamazepine and oxcarbazepine.
Oxcarbazepine (OCBZ), a 10-keto derivative of carbamazepine (CBZ) has been reported to have a similar range of efficacy and fewer unwanted effects than CBZ since it is a prodrug for the monohydroxy derivative (MHD). A cross-reactivity of only 1 in 4 has been reported between OCBZ and CBZ. For these reasons, we tried OCBZ with 3 consecutive patients with poorly controlled epilepsy who had had a therapeutic response to CBZ but in whom CBZ was discontinued because of serious skin reaction. Each patient had a similar skin response after exposure to only 600-900 mg OCBZ, which suggests a need to practice caution when substituting OCBZ for CBZ in patients known to have serious skin reaction to CBZ.
Beran
R G
RG
Liverpool Hospital, New South Wales, Australia.
D000328:Adult; D000368:Aged; D002220:Carbamazepine / Q000009:adverse effects* / Q000031:analogs & derivatives*; D003873:Dermatitis, Exfoliative / Q000139:chemically induced; D003875:Drug Eruptions / Q000209:etiology*; D004827:Epilepsy / Q000188:drug therapy*; D006801:Humans; D008297:Male; D000078330:Oxcarbazepine
D002220:Carbamazepine; D000078330:Oxcarbazepine